Business Wire

Kyowa Kirin Receives Positive CHMP Opinion for the Self-administration of CRYSVITA ® ▼ (burosumab) to Treat X-Linked Hypophosphataemia (XLH), a Rare Metabolic Bone Disorder

Share

Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended that CRYSVITA® (burosumab) be approved for the option of self-administration for the treatment of X-linked hypophosphataemia (XLH), a rare metabolic bone disease that impacts children and adults. The Committee indicated that, in addition to healthcare professionals, some patients or carers may be suitable to administer CRYSVITA, at the recommendation of the treating physician in its licensed indication for the treatment of XLH in children and adolescents aged 1 to 17 years with radiographic evidence of bone disease, and in adults.1

Abdul Mullick, President of Kyowa Kirin International, said: “The global pandemic has seen huge demands placed on healthcare systems, which has greatly impacted patient care. COVID-19 has also made some patients reluctant to visit healthcare facilities for fear of infection or of interrupting critical care of patients diagnosed with coronavirus. One of the ways in which Kyowa Kirin can help is by giving healthcare professionals increased flexibility to help patients receive treatment in the way that best suits their needs. The self-administration of CRYSVITA is a great example of meeting physician and patient needs and is one of the ways in which we are delivering on our purpose, to make people smile.”

CRYSVITA is administered by subcutaneous injection.2 CRYSVITA treatment will still need to be initiated by a physician experienced in the management of patients with metabolic bone diseases. Subsequently, if the patient is receiving a stable dose, the physician may recommend that administration can be performed by the patient or carer following appropriate training. The first self-administrated dose after drug initiation or dose change will need to be conducted under the supervision of a healthcare professional.

Dr Raja Padidela, Consultant Paediatric Endocrinologist at Royal Manchester Children’s Hospital, UK said: “Self-administration of medicines can help some patients maintain their independence and also empower them to take better control of their condition. In addition to XLH patients with mobility issues, this news could also be of benefit to parents of younger children with XLH, who may have less time to attend appointments at health centres or accommodate visits from home care nurses for administering injections. Many injectable treatments for chronic diseases, such as insulin for the treatment of diabetes mellitus, are successfully self-administered by patients. For XLH patients, the treating physician will assess which patients are appropriate, ensuring those self-administering are competent and comfortable doing so.”

The European Commission (EC) will review the CHMP recommendation and a final decision on the variation application to add the option of self-administration of CRYSVITA to the current approved SmPC is expected in the coming months. Self-administration of CRYSVITA remains unlicensed until the EC decision is issued.

▼This medicinal product is subject to additional monitoring.

About X-linked hypophosphataemia

X-linked hypophosphataemia (XLH) is a rare, genetic disease that causes abnormalities in the bones, muscles, and joints.2,3 XLH is not life-threatening, but its burden is life-long and progressive, and it may reduce a person’s quality of life.4

People with XLH have a genetic defect on the X-chromosome, which causes an excessive loss of phosphate through the urine and poor absorption from the gut, resulting in chronically low levels of phosphate in the blood.4,5 Phosphate is a key mineral needed for maintaining the body’s energy levels, muscle function, and the formation of healthy bones and teeth.6,7 While there is no cure for XLH, therapies aimed at helping to restore phosphate to normal levels within the body may help to improve the symptoms of the disease.8

XLH is the most common form of hereditary rickets.9 It can sometimes appear in individuals with no family history of the disease, but is usually passed down from a parent who carries the defective gene.10

About CRYSVITA® (burosumab)

CRYSVITA (burosumab) was created and developed by Kyowa Kirin and is a recombinant fully human monoclonal IgG1 antibody against the phosphaturic hormone fibroblast growth factor 23 (FGF23). FGF23 is a hormone that reduces serum levels of phosphate by regulating phosphate excretion and active vitamin D production by the kidney. Phosphate wasting and resulting hypophosphataemia in X-linked hypophosphataemia (XLH) is caused by excess FGF23. CRYSVITA is designed to bind to, and thereby inhibit, the biological activity of FGF23. By blocking excess FGF23 in patients, CRYSVITA is intended to increase phosphate reabsorption from the kidney and increase the production of active vitamin D, which enhances intestinal absorption of phosphate and calcium.

CRYSVITA has been available for clinical use since 2018. The first approval came from the European Commission, that granted a conditional marketing authorisation for CRYSVITA for the treatment of XLH with radiographic evidence of bone disease in children one year of age and older and adolescents with growing skeletons. In 2020, this authorisation was subsequently expanded to include older adolescents and adults.2

CRYSVITA is approved by the US Food and Drug Administration (FDA) for patients with XLH aged 6 months and older and by Health Canada for patients with XLH aged one year and older.11,12

In 2019, CRYSVITA received approval from Japan's Ministry of Health, Labour and Welfare for the treatment of FGF23-related hypophosphataemic rickets and osteomalacia. In 2020, CRYSVITA was reimbursed by National Health Insurance (NHI) in Japan as a self-injection presentation for the treatment of FGF23-related hypophosphataemic rickets and osteomalacia.

In January 2020, Swissmedic approved CRYSVITA for the treatment of adults, adolescents and children (one year of age and older) with XLH.13

Kyowa Kirin and Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE: Ultragenyx) have been collaborating in the development and commercialisation of CRYSVITA globally, based on the collaboration and licence agreement between Kyowa Kirin and Ultragenyx.

About Kyowa Kirin

Kyowa Kirin strives to create and deliver novel medicines with life-changing value. As a Japan-based Global Specialty Pharmaceutical Company with a heritage of 70+ -years, we apply cutting-edge science including an expertise in antibody research and engineering, to address the needs of patients and society across multiple therapeutic areas including Nephrology, Oncology, Immunology/Allergy and Neurology. Across our four regions – Japan, Asia Pacific, North America and EMEA/International – we focus on our purpose, to make people smile, and are united by our shared values of commitment to life, teamwork/Wa, innovation, and integrity. You can learn more about the business of Kyowa Kirin at:

https://www.kyowakirin.com/

Kyowa Kirin International

http://www.international.kyowa-kirin.com / www.kyowakirin.com

Galabank Business Park

Galashiels, TD1 1QH

United Kingdom

References


1 European Medicines Agency. CRYSVITA EPAR product information. Summary of Product Characteristics. Available at: https://www.ema.europa.eu/en/documents/product-information/crysvita-epar-product-information_en.pdf. Last updated: March 2020. Last accessed: May 2021.

2 Linglart A, Biosse-Duplan M, Briot K, et al. Therapeutic management of hypophosphatemic rickets from infancy to adulthood. Endocr Connect. 2014;3:R13-30.

3 Haffner D, Emma F, Eastwood DM, et al. Consensus Statement. Evidence-based guideline. Clinical practice recommendations for the diagnosis and management of X-linked hypophosphatemia. Nat Rev Nephrol. 2019;15;435-455.

4 Skrinar A, Dvorak-Ewell M, Evins A, et al. The lifelong impact of X-linked hypophosphatemia: Results from a burden of disease survey. J Endocr Soc. 2019;3:1321-1334.

5 Beck-Nielsen SS, Mughal Z, Haffner D, et al. FGF23 and its role in X-linked hypophosphatemia-related morbidity. Orphanet J Rare Dis. 2019;14:58.

6 Pesta D, Tsirigotis DN, Befroy DE, et al. Hypophosphatemia promotes lower rates of muscle ATP synthesis. The FAESB Journal. 2016;39:3378-3387.

7 Unnanuntana A, Rebolledo BJ, Khair MM, et al. Diseases affecting bone quality: beyond osteoporosis. Clin Orthop Relat Res. 2011;469:2194-2206.

8 Insogna KL, Rauch F, Kamenický P, et al. Burosumab improved histomorphometric measures of osteomalacia in adults with X-linked hypophosphatemia: a Phase 3, single-arm, international trial. J Bone Miner Res. 2019;34:2183-2191.

9 Carpenter TO, Imel EA, Holm IA, et al. A clinician's guide to X-linked hypophosphatemia. J Bone Miner Res. 2011;26:1381-8.

10 National Center for Advancing Translational Sciences. X-linked hypophosphatemia. Available at: https://rarediseases.info.nih.gov/diseases/12943/x-linked-hypophosphatemia. Last updated: February 2018. Last accessed: April 2021.

11 Health Canada. Regulatory Decision Summary – CRYSVITA. Available at: https://hpr-rps.hres.ca/reg-content/regulatory-decision-summary-detail.php?linkID=RDS00463. Last updated: April 2020. Last accessed: April 2021.

12 Available at : https://www.kyowakirin.com/media_center/news_releases/2019/e20190930_01.html. Last accessed: April 2021

13 Swissmedic. Crysvita, injektionslösung (burosumabum). Available at: https://www.swissmedic.ch/swissmedic/en/home/humanarzneimittel/authorisations/new-medicines/vrysvita-injektionsloesung_burosumabum.html. Last updated: January 2020. Last accessed: April 2021.

KKI/INT/BUR/0940

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Contacts for Kyowa Kirin Co., Ltd.:
Media
Hiroki Nakamura
+81-3-5205-7205
Email: media@kyowakirin.com

Contacts for Kyowa Kirin International:
Media
Stacey Minton
+44 (0) 7769 656073
Email: Stacey.Minton@kyowakirin.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Nucleai and Merck KGaA Darmstadt, Germany Launch Translational Medicine Collaboration Utilizing Nucleai’s AI-Powered Biomarker Platform24.6.2021 17:17:00 CEST | Press release

Nucleai (www.nucleaimd.com), a precision medicine company using AI-powered image analysis technology to support novel pathology-based biomarker development, and Merck KGaA, Darmstadt, Germany, a leading science and technology company, announced that they have entered into a long-term collaboration to leverage Nucleai's image analysis and biomarker discovery platform for several Merck KGaA, Darmstadt, Germany clinical stage oncology assets. As part of the collaboration, Merck KGaA, Darmstadt, Germany will leverage Nucleai’s platform for exploratory research, with the potential to further develop identified pathology-based biomarkers as companion diagnostics. The collaboration will further utilize Nucleai’s technology to expand onto Merck KGaA, Darmstadt, Germany’s analysis capabilities, enabling faster turnaround time and scale for future studies. Nucleai's platform analyzes tissue images using computer vision and machine learning methods to model the tumor and the immune system's spati

Andersen Global Enters Collaboration Agreement With One of Lesotho’s Largest Law Firms24.6.2021 15:30:00 CEST | Press release

Andersen Global extends its African presence through a Collaboration Agreement with one of Lesotho’s largest law firms, Webber Newdigate Attorneys, enhancing the organization’s coverage in the southern region of the continent. Webber Newdigate Attorneys, established in 1978, is located in the capital city, Maseru. Recognized by Chambers Global and consistently awarded by PMR Africa, the full-service firm provides legal services to both local and international clients including individuals, companies, multinationals, government authorities, banks and parastatal organizations. The firm also covers a range of industries with capabilities in tax, real estate, employment law, corporate and commercial, litigation, banking and finance, mining and resources, immigration and family law. “For more than 40 years, our team has consistently delivered high-quality solutions to our clients, including those of an intricate nature,” said Partner Alex de Wet. “Andersen Global’s culture echoes our firm’s

New Outseer Fraud & Payments Report Confirms Massive Increase in Brand Abuse Cyber Attacks, Jumping 158% From Q1 202024.6.2021 15:00:00 CEST | Press release

Outseer has published its latest quarterly fraud and payments report, uncovering a significant spike in brand abuse attacks and a continued shift to more precise payment authentication methods. The Q2 installment of the report features insights from January through March of 2021 as captured through the Outseer Global Data Network, and collected while authenticating consumer transactions and investigating threats on behalf of Outseer customers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210624005352/en/ (Graphic: Business Wire) According to the report, Brand Abuse attacks impersonating companies through social media and published content now represents the majority of fraud attacks, growing from 27% in Q4 2020 to 68% in Q1 2021. This dramatic shift is attributed to the increased use of digital platforms including social media, web publishing, and cloud-based collaboration tools during the pandemic – all fertile hunting gr

IATA Strengthens Operational Scalability By Switching to Rimini Street for Integrated Support and Application Management Services for its SAP Applications24.6.2021 15:00:00 CEST | Press release

Rimini Street, Inc. (Nasdaq: RMNI), a global provider of enterprise software products and services, the leading third-party support provider for Oracle and SAP software products and a Salesforce partner, today announced that International Air Transport Association (IATA), the leading commercial aviation trade association headquartered in Montreal, Canada, has switched to Rimini Street Support and Application Management Services (AMS) for its SAP ECC 6.0 and Business Objects applications. With the commercial aviation sector heavily affected by the COVID-19 pandemic, IATA made strategic business decisions to navigate the crisis, including outsourcing key elements of its IT service delivery to reduce operating costs. As a result of switching to Rimini Street, the organization now benefits from a unified support solution that integrates application support and managed services, enabling IATA to meet business demand in a post-pandemic recovery. This press release features multimedia. View t

XPeng Inc. Launches Hong Kong Public Offering24.6.2021 14:59:00 CEST | Press release

XPeng Inc. (“XPeng” or the “Company”, NYSE: XPEV), a leading Chinese smart electric vehicle (“Smart EV”) company, today announced the launch of its Hong Kong public offering (the “Hong Kong Public Offering”), which forms part of the global offering (the “Global Offering”) of 85,000,000 new Class A ordinary shares of the Company (the “Offer Shares”) and listing of its Class A ordinary shares on the Main Board of The Stock Exchange of Hong Kong Limited (the “Hong Kong Stock Exchange”) under the stock code “9868” (the “Proposed Listing”). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210624005620/en/ XPeng P7 Wing edition (Photo: Business Wire) The Company’s American depositary shares (the “ADSs”), each representing two Class A ordinary shares of the Company, will continue to be listed and traded on the New York Stock Exchange (“NYSE”). The Proposed Listing is a dual-primary listing of the Class A ordinary shares of the Compan

Skyworks Aeronautics Announces the Order of 100 eGyro™ Electric Aircraft with Options for an Additional 100 by a Consortium of Mint Air and Mobius.energy24.6.2021 14:15:00 CEST | Press release

Today, Skyworks Aeronautics (“Skyworks”) announces the order of 100 eGyro™ electrically powered vertical take-off and landing (eVTOL) aircraft from a consortium of Mint Air (“Mint”) and Mobius.energy Corp (“Mobius”) with options for an additional 100 aircraft. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210624005323/en/ Notional depiction of the Skyworks eGyro™ (Photo: Business Wire) “A consortium led by Mint Air is committed to bringing safe, efficient, and cost-effective electric aircraft solutions to South Korea and we are absolutely thrilled they have selected our eGyro as their aircraft of choice to initiate operation of the leading eVTOL service in Korea. We look forward to performing our first public demonstrations of the eGyro in Korea and to launching the eGyro Urban Air Mobility (UAM) platform in the Korean market,” said John Michel, Co-Founder & Executive Director of Skyworks. “We are pleased to announce the Sk

Esri Releases New 2020 Global Land Cover Map24.6.2021 14:00:00 CEST | Press release

Esri, the global leader in location intelligence, today announced it is releasing for the first time ever a new high-resolution, 2020 global land cover map as part of the company’s Living Atlas. The map was built using European Space Agency (ESA) Sentinel-2 satellite imagery, and developed using a new machine learning workflow teaming with new Esri Silver Partner Impact Observatory, as well as long-time partner Microsoft. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210624005176/en/ Esri releases first-ever high-resolution (10-meter), 2020 global land cover map (Photo: Business Wire) The new map will be updated annually supporting change detection and highlighting planetary land changes, especially related to the effects of human activity. A consistent map of land cover for the entire world based on the most current satellite information, the 2020 Global Land Cover Map can be combined with other data layers for green infra